公开(公告)号：CA3034876A1

公开(公告)日：2018-03-01

申请号：CA3034876

申请日：2017-08-23

Applicant: CHO PHARMA INC ,  ACADEMIA SINICA ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：AU2017315677B2

公开(公告)日：2021-03-11

申请号：AU2017315677

申请日：2017-08-23

Applicant: ACADEMIA SINICA ,  CHO PHARMA INC

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：CA3034876C

公开(公告)日：2022-10-04

申请号：CA3034876

申请日：2017-08-23

Applicant: CHO PHARMA INC ,  ACADEMIA SINICA ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high transglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：AU2017315677A1

公开(公告)日：2019-04-11

申请号：AU2017315677

申请日：2017-08-23

Applicant: ACADEMIA SINICA ,  CHO PHARMA INC ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：AU2020325204A1

公开(公告)日：2022-01-06

申请号：AU2020325204

申请日：2020-08-05

Applicant: CHO PHARMA INC

Inventor： CHU KUO-CHING ,  HUANG LIN-YA ,  ZENG YI-FANG

IPC: C12N9/28 ,  C07K14/195 ,  C07K16/00 ,  C12N9/24 ,  C12N15/62

Abstract: The present disclosure provides a fusion protein comprising a fucosidase or a truncated fragment or a mutant thereof fuses with either N-terminal end or C-terminal end of the endoglycosidase or a truncated fragment of mutant thereof. The present disclosure also provides a nucleic acid molecule expressing the fusion protein and a method for remodeling a glycan of an antibody Fc region.

公开(公告)号：CA3143262A1

公开(公告)日：2021-02-11

申请号：CA3143262

申请日：2020-08-05

Applicant: CHO PHARMA INC

Inventor： CHU KUO-CHING ,  HUANG LIN-YA ,  ZENG YI-FANG

IPC: C12N9/24 ,  C07K16/00 ,  C07K19/00 ,  C12N9/96 ,  C12N15/56 ,  C12N15/62 ,  C12P21/00 ,  C12P21/08

Abstract: The present disclosure provides a fusion protein comprising a fucosidase or a truncated fragment or a mutant thereof fuses with either N-terminal end or C-terminal end of the endoglycosidase or a truncated fragment of mutant thereof. The present disclosure also provides a nucleic acid molecule expressing the fusion protein and a method for remodeling a glycan of an antibody Fc region.